Chlamydia Infections - Pipeline Review, H1 2015

Published: Apr, 2015 | Pages: 76 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Chlamydia Infections - Pipeline Review, H1 2015

Summary 

Global Markets Direct's, 'Chlamydia Infections - Pipeline Review, H1 2015', provides an overview of the Chlamydia Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chlamydia Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chlamydia Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chlamydia Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Chlamydia Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Chlamydia Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Chlamydia Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reason To Buy 

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Chlamydia Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Chlamydia Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Chlamydia Infections Overview 8
Therapeutics Development 9
Pipeline Products for Chlamydia Infections - Overview 9
Pipeline Products for Chlamydia Infections - Comparative Analysis 10
Chlamydia Infections - Therapeutics under Development by Companies 11
Chlamydia Infections - Therapeutics under Investigation by Universities/Institutes 12
Chlamydia Infections - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Chlamydia Infections - Products under Development by Companies 16
Chlamydia Infections - Products under Investigation by Universities/Institutes 17
Chlamydia Infections - Companies Involved in Therapeutics Development 18
Abera Bioscience AB 18
Adamis Pharmaceuticals Corporation 19
Big DNA Ltd. 20
CEL-SCI Corporation 21
Foamix Pharmaceuticals Ltd. 22
Genocea Biosciences, Inc. 23
Merck & Co., Inc. 24
Osel Inc. 25
Prokarium Ltd. 26
QureTech Bio AB 27
Chlamydia Infections - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Target 29
Assessment by Mechanism of Action 31
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
Ab-03 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
acALY-18 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
BDNA-003 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Biologic for Infectious Disease - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
C-31G - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
CEL-1000 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
chlamydia trachomatis vaccine - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
chlamydia vaccine - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
chlamydia vaccine - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
chlamydia vaccine - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
chlamydia vaccine - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
chlamydia vaccines - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Drugs to Block Virulence for Chlamydia Infections - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
GEN-001 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
minocycline Gel - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Peptides to Inhibit CPAF for Chlamydia Infections - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Small Molecules for Chlamydophila Infections - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Small Molecules to Target Heparan Sulphate Proteoglycan for Bacterial and Viral Infections - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
solithromycin - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
VNI-201 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Chlamydia Infections - Recent Pipeline Updates 61
Chlamydia Infections - Dormant Projects 70
Chlamydia Infections - Product Development Milestones 71
Featured News & Press Releases 71
Aug 12, 2014: Cempra Initiates Phase 3 Clinical Trial in Patients With Uncomplicated Gonorrhea Infection 71
Jul 20, 2011: Newly Designed Molecule Blocks Chlamydia Bacteria 71
Apr 26, 2010: Foamix is granted a fourth U.S. patent for OilGel, directed to pharmaceutical compositions and their dermatological, gynecological and ophthalmic applications 72
Dec 15, 2009: Genocea Biosciences Awarded Grant For The Development Of Chlamydia Vaccines From The University Of Pittsburgh Medical Center's Sexually Transmitted Infections Cooperative Research Center 73
Sep 13, 2007: Possible Vaccine Target For Chlamydia Identified 73
Appendix 75
Methodology 75
Coverage 75
Secondary Research 75
Primary Research 75
Expert Panel Validation 75
Contact Us 75
Disclaimer 76

List of Tables

Number of Products under Development for Chlamydia Infections, H1 2015 9
Number of Products under Development for Chlamydia Infections - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Number of Products under Investigation by Universities/Institutes, H1 2015 12
Comparative Analysis by Late Stage Development, H1 2015 13
Comparative Analysis by Clinical Stage Development, H1 2015 14
Comparative Analysis by Early Stage Development, H1 2015 15
Products under Development by Companies, H1 2015 16
Products under Investigation by Universities/Institutes, H1 2015 17
Chlamydia Infections - Pipeline by Abera Bioscience AB, H1 2015 18
Chlamydia Infections - Pipeline by Adamis Pharmaceuticals Corporation, H1 2015 19
Chlamydia Infections - Pipeline by Big DNA Ltd., H1 2015 20
Chlamydia Infections - Pipeline by CEL-SCI Corporation, H1 2015 21
Chlamydia Infections - Pipeline by Foamix Pharmaceuticals Ltd., H1 2015 22
Chlamydia Infections - Pipeline by Genocea Biosciences, Inc., H1 2015 23
Chlamydia Infections - Pipeline by Merck & Co., Inc., H1 2015 24
Chlamydia Infections - Pipeline by Osel Inc., H1 2015 25
Chlamydia Infections - Pipeline by Prokarium Ltd., H1 2015 26
Chlamydia Infections - Pipeline by QureTech Bio AB, H1 2015 27
Assessment by Monotherapy Products, H1 2015 28
Number of Products by Stage and Target, H1 2015 30
Number of Products by Stage and Mechanism of Action, H1 2015 32
Number of Products by Stage and Route of Administration, H1 2015 34
Number of Products by Stage and Molecule Type, H1 2015 36
Chlamydia Infections Therapeutics - Recent Pipeline Updates, H1 2015 61
Chlamydia Infections - Dormant Projects, H1 2015 70